4Latil A, Bieche I, Pesche S, et al. VEGF over expression in elin- icaUy localized prostate tumors and neuropilin - 1 over expression in metastatic forms Int J Cancer, 2000, 89: 167.
5Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prosta- tectomy. Long term results J Urol, 2004, 172:2252 -2255.
6Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor - 3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res, 2004, 10:5137-5144.
7Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAF V600E in thyroid ceils of transgenic mice results in papillary thy- roid cancers that undergo dedifferentiation. Cancer Res, 2005, 65 (10) :4238 -4245.
8Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic - patterns associated with BRAF and KRAS mutations in colorec- tal neoclassic. Cancer Res, 2004, 62 (22) : 6451 - 6455.
10Kalakonda S, Nallar SC, Lindner D J, et al. Tumor suppressive activity of the cell death activator GRIM - 19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res. 2007, 67 ( 13 ) : 6212 - 6220.
7Camlica H,Duranyildiz D,Oguz H,et al.The diagnostic value of macrophage migration inhibitory factor(MIF)in gastric cancer[J].Pathol Oncol Res,2008,14(1):79-83.
8Katherine L,Meyer-Siegler DF,Michael A.Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as aiomarkerinpafientswithprostate carcinarma[J].Cancer,2002,94(5):1449-1456.
9Meyer-Siegler KL,Iczkowski KA.Vera PL.Further evidence for Increased macrophage migration inhibitory factor expression in prostate cancer[J].BMC Cancer,2005,5(1):73.
10Ren Y,Law S,Huang X,et al.Maerophagemigrationilnhibitory factor stimulates angiogenic factor expressionand correlates With dfferentiation and lymph node status in patients with esophageal squamous cell carcinoma[J].Ann Surg.2005,242(1):55-63.
